Share this article

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, has launched a multimarker methylation prognostic test for grading gliomas, a common type of brain cancer.

The DNA methylation test analyses eight genes for differential methylation on formalin fixed paraffin embedded (FFPE) tumour samples to determine the glioma CpG island methylation phenotype (G-CIMP) score which correlates with patient survival.

Developed and validated by RCSL and commercialised and marketed by Castle Biosciences, the biomarker assay provides improvements in sensitivity, patient sample requirements and reproducibility over the bisulfite DNA methylation platform by leveraging RiboMed’s bisulfite-free Abscription-based MethylMeter platform.

RiboMed CEO Michelle Hanna said the unparalleled sensitivity, accuracy and reproducibility offered by the Abscription-based G-CIMP test, coupled with its ability to assess multiple methylation biomarkers in FFPE patient samples, makes it ideal for prognostic glioma testing.

“Furthermore, MethylMeter is directly applicable to the development of a broad range of new diagnostic, theranostic and companion diagnostic DNA methylation based assays, particularly those utilising FFPE samples,” Hanna added.

The purpose of the G-CIMP biomarker test is to provide objective information to improve grade-related prognosis, the company said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Castle Biosciences CEO Derek Maetzold said when traditional bisulfite-based technologies were found to be unsuitable for the FFPE assay, RiboMed’s bisulfite-free methylation detection platform effectively circumvented the problems associated with the traditional technologies, enabling the rapid development of an accurate and reproducible FFPE glioma tumour assay.

“We are very excited to partner with RiboMed in offering the DecisionDX G-CIMP test since it will significantly improve glioma tumour grading and become the standard of care for these patients,” Maetzold added.

RCSL offers sensitive and quantitative DNA methylation profiling clinical assay development services, which provide reliable results, even with FFPE tissues.